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Abstract
Background: Epidermolysis bullosa (EB) belongs to a family of rare heterogeneous, genetic disorders characterized
by blistering of the skin and mucous membranes in response to minor mechanical trauma. The involvement of the
oral mucosa and oesophagus stenosis is suggested to be responsible for severe nutritional deficiencies, but few
studies have till now considered this aspect. This observational study aimed to evaluate homocysteine status in
children and adolescents with EB by assessing total plasma homocysteine (tHcy) and metabolically related vitamins
(B6, B12, folate) concentrations.
Methods: Twenty EB patients (12 M; age range 0.5−19 years) were evaluated for: plasma tHcy, serum B12 and
holotranscobalamin (HoloTC, the active fraction of B12), serum and erythrocyte folate (s-F and Ery-F, respectively),
plasma B6 and serum high sensitive C-reactive-protein (hsCRP) levels. Clinical severity was also evaluated through
the Birmingham Epidermolysis Bullosa Severity (BEBS) score. A sex and age well-matched population was also
enrolled.
Results: EB patients showed tHcy levels higher (p = 0.04) and B6 levels lower (p = 0.03) than controls. B12, HoloTC, s-F
and ery-F concentrations did not differ between patients and controls. Multiple linear regression analysis showed that
tHcy levels were independent of the metabolically related vitamins levels. In addition, serum hsCRP levels were higher
in EB patients than in controls (p = 0.003) and correlated negatively with B6 concentrations (r = -0.6; p = 0.009). BEBS
score correlated negatively with HoloTC (p = 0.022) and B6 (p = 0.005) levels and positively with age (p = 0.031) and
hsCRP levels (p < 0.001).
Conclusions: The assessment of tHcy and metabolically related vitamin levels describes an important aspect of EB
patients’ nutritional status which can result essential for their long term care. Monitoring B6 levels in EB patients could
be particularly important in order to prevent several complications associated with B6 deficiency and to avoid a B6
excess which sustains an inflammatory condition.
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Background
Epidermolysis bullosa (EB) belongs to a family of inherited
autosomal (dominant or recessive) skin disorders. It is
characterized by recurrent blistering formation of the skin
and mucous membranes in response to minor mechanical
trauma. The blisters easily rupture, and the resulting
erosions and ulcerations are prone to infection [1, 2].
EB is classified into four main types, depending on the
level of epidermal separation from the underlying basal
lamina: EB Simplex (EBS), Junctional EB (JEB),
Dystrophic EB (DEB), Kindler Syndrome (KS) [3]. Be-
cause of the involvement of the oral mucosa and
oesophagus stenosis, EB patients, especially JEB and
DEB types, are at risk of severe nutritional deficiencies,
such as B vitamins group deficiencies (vitamin B6, vita-
min B9 or folate, vitamin B12). This may be due to oral,
oesophageal, and oropharyngeal problems (oral blister-
ing and ulcerations, abnormal oesophageal motility,
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oesophageal strictures, dysphagia, and dental problems);
digestion and absorption problems; anal erosions; fis-
sures, and rectal strictures resulting in chronic constipa-
tion; loss of blood and protein through open skin
blisters; and hyper-metabolism resulting in increased
heat loss and protein turnover, especially in the setting
of skin infections. These complications affect all infants,
children, and adolescents with EB due to higher nutri-
tional needs required for growth [2].
Hyperhomocysteinemia (HHcy) may be a result of one
or more B vitamins group depletion and has been asso-
ciated with several diseases, e.g. cardiovascular disease,
Alzheimer disease and other dementias, peripheral neur-
opathy, renal failure and hypothyroidism [4–6]. More-
over, recent studies have demonstrated the involvement
of homocysteine (Hcy) both in the enhancement of
inflammatory activation and in autoimmunity triggering
mechanisms, thus suggesting a possible role for Hcy not
only in the development of cardiovascular disease but
also in the pathogenesis of autoimmune diseases [7].
Since Hcy metabolism is catalysed by enzymes requiring
B vitamins as cofactors, high total Hcy levels (tHcy) can
indicate undernourishment due to a lack of metabolic-
ally related vitamins: in particular vitamin B12, holotran-
scobalamin (HoloTC, the biologically active form of B12)
[8] and/or folate, cofactors for the re-methylation
pathway, and B6 for the transulfuration pathway [4].
Up to now few studies have taken into consideration
EB patients’ nutritional deficiencies. To the best of our
knowledge, this is the first study aimed at evaluating
Hcy status by assessing tHcy and metabolically related
vitamins levels in EB patients.
Methods
Subjects
Twenty consecutive EB children and adolescents (12 M/
8 F; age range 0.5–19 years) were enrolled at the
Pediatric Highly Intensive Care Unit of Fondazione
IRCCS Cà Granda, Ospedale Maggiore Policlinico,
Milan, Italy.
EB types were classified based on genetic, immuno-
fluorescence mapping results, and clinical features,
according with Fine JD. et al. [3].
Type analysis identified 6 cases of EBS (30 %), 1 case
of JEB (5 %), 11 cases of DEB (55 %) and 2 cases of KS
(10 %). Among DEB patients, 3 cases (27.3 %) were
dominant dystrophic epidermolysis bullosa (DDEB) and
8 cases (72.7 %) were recessive dystrophic epidermolysis
bullosa (RDEB).
In all patients, disease severity was also evaluated
through the Birmingham Epidermolysis Bullosa Severity
(BEBS) score. This score takes into account: area of
damaged skin; involvement of nails, mouth, eyes, larynx
and oesophagus; scarring of hands; skin cancer; chronic
wounds; alopecia; nutritional compromise. Area was
allocated 50 points, and the 10 other items 5 points
each, giving a maximum score of 100 [9]. The BEBS
score was performed by the paediatrician who regularly
followed the patients (SG) at blood sample collection.
EB patients were compared with a healthy and well-
matched age and gender control population (12 M/8 F;
age range 1–19 years).
The study protocol was approved by the Ethics Com-
mittee of the Fondazione IRCCS Ca’ Granda Ospedale
Maggiore Policlinico, Milan, Italy (Registration number:
2014–359), and conducted in accordance with the stan-
dards of Good Clinical Practice for trials of medicinal
products in humans. The informed written consent of a
parent or legal guardian was required for subjects aged
<18, and the subjects aged ≥8 were asked to give their
written assent. Patients’ parents and patients >8 years
gave their written consent to data publication. Ethics
Committee also approved data publication.
Nutritional status
Children with severe EB tend to be short and under-
weight for their age. Nutritional status assessment was
conducted by anthropometry. Patients and controls’
height and weight were measured under standard condi-
tions by the same nurse, always using the same measur-
ing equipment; Body Mass Index (BMI) was calculated.
Weight, height and BMI for age were evaluated using
Cacciari E. et al. growth curves [10].
Biochemical analysis
Plasma tHcy and B6, serum folate (s-F), B12 and HoloTC,
erythrocyte (ery-F) levels were measured in order to
evaluate homocysteine metabolism. Serum high sensitive
C reactive protein (hsCRP) was also assessed.
Blood samples were drawn in the morning, after an
overnight fast. Two blood specimens from each patient
were collected in light protected tubes, either with no
additive (for serum B12, HoloTC, s-F and hsCRP) or
containing ethylenediaminetetracetic acid (EDTA) to
prevent coagulation, for ery-F, tHcy and B6 concentra-
tion assays. EDTA specimens were immediately put on
ice and, after collecting whole blood aliquots for
complete blood count and ery-F determination, were
centrifuged within 30 min in order to obtain plasma
samples for tHcy and B6 determination. Serum and
plasma samples were frozen and stored at -80 ° C until
analysed.
Plasma tHcy and serum B12 concentrations were
determined by immunoenzymatic assay using the rele-
vant commercial kits on AIA 600II analyser (Tosoh
Bioscience, Tokyo, Japan), while HoloTC, s-F and ery-F
by means of immunoenzymatic assay using the relevant
commercial kits on Architect analyser i2000SR (Abbott
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Diagnostics, Abbott Park, IL, USA). Plasma B6 concen-
trations were evaluated by HPLC method using the
relevant commercial kit (Chromsystems Instruments &
Chemicals, Munich, Germany). HsCRP levels were
assessed by immunoenzymatic assay using the relevant
commercial kit on Modular P analyzer (Roche,
Switzerland).
Because of the continuous physiological changes that
occur throughout childhood, appropriately partitioned
pediatric reference values are not readily available. For
this reason, tHcy levels and metabolically related
vitamins of EB patients were compared to those of a
healthy population well-matched age and gender.
In addition, in our study, hyperhomocysteinemia and
B12 deficiency were defined according to the reference
intervals and cut-off values described by Bailey D. et al.
in the Canadian Laboratory Initiative for Pediatric
Reference Intervals (CALIPER) program [11] (Table 3),
while B6, s-F and ery-F levels were compared to the data
obtained from a meta-analysis which described biochem-
ical vitamin-status data in different groups of the
Spanish population [12] (Table 3). Particularly, assuming
that B6, s-F and ery-F were normally distributed, we con-
sidered as reference interval the mean vitamins levels
obtained in the Spanish Population, taking two standard
deviations either side of the mean [12].
HoloTC levels were classified by using the relevant
cut-off value for adult population [8] as any study has
not yet performed in children and adolescent.
Statistical analysis
Results, reported as the median value with InterQuartile
Range (IQR; 25–75 percentiles), were analyzed using the
Mann-Whitney test to assess any difference between EB
patients and controls. In addition, because of the small
number of JEB and KS subjects, only EBS and DEB
groups’ Hcy metabolically related vitamins and hsCRP
levels were compared.
Multiple linear regression analysis was used to find
predictors of homocysteine values. Pearson’s coefficient
was used to test the correlation between continuous var-
iables. The statistical analysis was performed by using
Stata 13 (StataCorp. 2013, Stata: Release 13 Statistical
Software. College Station, TX: StataCorp LP).
Results
Demographic characteristics and growth outcomes of
patients and controls are reported in Table 1.
With regard to weight, 35 % (n = 7) and 10 % (n = 2) of
patients and controls, respectively, were below the 3rd
percentile (p = 0.13); particularly, among these patients,
57 % were DEB (n = 4; RDEB), 29 % were EBS (n = 2)
and 14 % were JEB (n = 1).
In regard to height, only 2 subjects were under the 3rd
percentile both in patients and in controls. Forty percent
of patients (n = 8) and 20 % of controls (n = 4) had a
BMI below the 3rd percentile (p = 0.30); among these pa-
tients, 50 % were DEB (n = 4; RDEB), 37.5 % were EBS
(n = 3) and 12.5 % were JEB (n = 1).
In addition, 1 DDEB patient (BEBS score = 2) showed
both weight between the 90th-97th percentile and BMI
>95th percentile; 1 EBS patient (BEBS score = 1) reported
BMI > 95th percentile.
Controls showed both weight and BMI under the 90th
percentile.
Among DEB patients, 5 of them (45.5 %) had
oesophagus stenosis. Only one patient (JEB) was celiac
while any other patients did not present clinical signs
and symptoms of malabsorption.
BEBS score ranged from 2 to 67 points (Table 2).
Although we did not reported daily caloric and nutri-
ent intake of our patients, 25 % of EB subjects (n = 4; 1
KS patient and 3 DEB patients) were taking calorically
dense liquid supplements fortified with vitamins and
minerals orally, containing vitamin B12, B6 and folic acid.
Another 25 % of them (n = 4; 1 EBS patients, 3 DEB pa-
tients and 1 JEB patient) were supplemented only with
vitamin B12. However the supplemented vitamin doses
were less than the Italian Official Recommendation
(IOR) vitamin intake [13].
Both EB patients and controls had normal renal func-
tions (data not shown). The presence of microcytic an-
aemia was highlighted in 45 % of EB patients while
controls’ hematologic parameters were within the rele-
vant reference intervals (data not shown).
Biochemical parameters of patients and controls are
listed in Table 3; results were reported as median
value;interquartile range (median;IQR).
Plasma tHcy levels were significantly higher in EB
patients than in controls (9.9;7.5–10.5 μmol/L vs
6.5;5.8–8.4 μmol/L; p = 0.04) (Fig. 1a) and 55 % of
patients showed tHcy levels above the cut-off value
(10.4;10.1-10.9 μmol/L), according to CALIPER pro-
gram’s reference interval [11]. Particularly, DEB patients
showed significantly higher tHcy concentrations than
controls (10.0;8.3-10.6 μmol/L vs 6.5;5.8-8.4 μmol/L; p =
0.03), while EBS patients’ tHcy levels did not differ
significantly from controls’ levels (9.4;6.5-10.4 μmol/L vs
6.5;5.8-8.4 μmol/L; p = 0.25).
The evaluation of the Hcy metabolically related vita-
mins highlighted altered plasma B6 levels in 70 % of EB
patients [12] and, interestingly, B6 levels were signifi-
cantly lower in EB patients than in controls (6.9;4.2-
12.3 μg/L vs 11.3;9.2-14.3 μg/L; p = 0.03) (Fig. 1b). More-
over, B6 levels were significantly lower both in patients
with weight <3rd percentile compared to the other
patients (3.6;1.8-6.3 μg/L vs 9.1;6.9-18.3 μg/L; p = 0.03)
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and in patients with a BMI <3rd percentile (4.6;2.3-
6.2 μg/L vs 9.6;7.5-20.0 μg/L, p = 0.01) compared to the
other patients.
S-F levels were altered in 50 % of EB subjects [12],
and were significantly lower both in patients with
weight <3rd percentile compared to the other patients
(8.6;6.1-10.4 nmol/L vs 13.8;10.4-22.4 nmol/L; p =
0.05) and in patients with BMI <3rd percentile
(7.6;5.8-9.9 nmol/L vs 15.9;11.0-23.3 nmol/L; p = 0.01)
compared to the other patients. However median s-F
concentrations between patients and controls did not
show any difference (p = 0.64).
Serum B12 and HoloTC levels were normal both in
most of EB patients and controls, according to Bailey D.
et al. [11] and Bamonti F. et al studies [8], respectively.
No differences between patients and controls were
observed in B12, HoloTC and ery-F levels.
However, interestingly, HoloTC concentrations were
lower both in patients whose weight was under the 3rd
percentile, compared to the other EB patients (83.0;71.6-
99.7 pmol/L vs 126.0;93.9-128.0 pmol/L; p = 0.09) and in
patients with BMI <3rd percentile (90.5;74.6-99.2 pmol/L
vs 128.0;92.8-128.0 pmol/L; p = 0.08), compared to the
other EB patients.
Despite the altered levels of B6 and s-F, multiple linear
regression analysis showed that tHcy levels were inde-
pendent of the metabolically related vitamins levels.
Serum hsCRP levels were significantly higher in EB
patients than in controls (p = 0.003), altered in 50 % of
patients, (Fig. 1c) and higher depending on the severity
of EB type. In fact, hsCRP median levels were signifi-
cantly higher both in DEB patients than controls
(3.0;0.2-5.4 mg/dL vs 0.04;0.03-0.1 mg/dL; p = 0.000) and
in DEB than in EBS patients (3.0;0.2-5.4 mg/dL vs
0.2;0.03-1.0, mg/dL; p = 0.04).
Table 1 Demographic characteristics and growth outcomes of
patients and controls
EB patients (n = 20) Controls (n = 20) p*
Sex (M/F) 12/8 12/8 n.a.
age (years) 8.0;6.5-12.5 6.1;5.5-13 0.89
Growth outcomes
Weight for agea n = 20 n = 20
< 3 p 35 % (7) 10 % (2) 0.13
3-10 p 10 % (2) 15 % (3) 0.99
10-25 p 15 % (3) 10 % (2) 0.99
25-50 p 10 % (2) 35 % (7) 0.13
50-75 p 20 % (4) 15 % (3) 0.99
75-90 p 5 % (1) 15 % (3) 0.60
90-97 p 5 % (1) 0 % (0) 0.99
Height for agea n = 20 n = 20
< 3 p 10 % (2) 10 % (2) 0.60
3-10 p 20 % (4) 20 % (4) 0.60
10-25 p 15 % (3) 10 % (2) 0.99
25-50 p 25 % (5) 20 % (4) 0.99
50-75 p 15 % (3) 5 % (1) 0.60
75-90 p 10 % (2) 15 % (3) 0.99
90-97 p 5 % (1) 20 % (4) 0.34
BMI (Kg/m2)a n = 20 n = 20
< 3 p 40 % (8) 20 % (4) 0.30
3-10 p 5 % (1) 15 % (3) 0.60
10-25 p 20 % (4) 10 % (2) 0.66
25-50 p 20 % (4) 20 % (4) 0.69
50-75 p 5 % (1) 25 % (5) 0.18
75-90 p 0 % (0) 10 % (2) 0.47
90-95 p 0 % (0) 0 % (0) n.a.
95-97 p 5 % (1) 0 % (0) 0.99
> 97 p 5 % (1) 0 % (0) 0.99
Demographic characteristics are reported as median;IQR while growth
outcomes are reported as percentage values and (number of subjects). * Mann-
Whitney test for age and chi-square test for growth outcomes; n.a not
applicable; a Cacciari E. et al. [10]
Table 2 The Birmingham Epidermolysis Bullosa Severity (BEBS)
score of EB patients
Patient Sex
(F: female; M: male)
Age
(years)
EB classification BEBS score
1 F 6 DDEB 2
2 M 8 KS 15
3 M 11 KS 17
4 M 19 RDEB 60
5 F 13 RDEB 50
6 M 10 EBS 8
7 F 7 RDEB 40
8 M 13 RDEB 65
9 M 3 RDEB 27
10 M 3 EBS 3
11 M 18 JEB 34
12 F 7 RDEB 32
13 M 8 EBS 1
14 F 3 EBS 25
15 F 13 EBS 17
16 M 0.5 EBS 3
17 M 7 DDEB 2
18 M 12 DDEB 1
19 F 7 RDEB 34
20 F 10 RDEB 67
EBS Epidermolysis Bullosa Simplex, JEB Junctional Epidermolysis Bullosa, DDEB
Dominant Dystrophic Epidermolysis Bullosa, RDEB Recessive Dystrophic
Epidermolysis Bullosa, KS Kindler Syndrome
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A negative correlation was found between hsCRP
levels and B6 levels (r = -0.6; p = 0.009) (Fig. 1d).
Finally, BEBS score correlated negatively with HoloTC
(r = -0.5; p = 0.022) and B6 (r = -0.6; p = 0.005) levels and
positively with age (r = 0.5; p = 0.031) and hsCRP levels
(r = 0.8; p < 0.001).
Discussion
Hyperhomocysteinemia, a marker for folate, B12 and B6
deficiency, has been associated with enhancement of in-
flammatory activation and with autoimmunity triggering
mechanisms [7]. Patients with EB suffer from acute and
chronic malnutrition. In fact, in these patients,
oesophagus stenosis and oral mucosa erosions are re-
sponsible for restricted ingestion, and protein-calorie
malnutrition is worsened by losses from cutaneous blis-
ters and by chronic inflammatory syndrome secondary
to chronic skin infection [2]. Therefore, nutritional man-
agement is an essential aspect of the long term care of
patients with EB because protein, vitamin and trace
element intakes are essential for growth and wound
healing and for the host resistance against bacterial
infections.
Nowadays few studies have described vitamin status in
EB. A previous study by Ingen-Housz-Oro S. et al. [14],
described vitamin and trace metal status of 14 recessive
DEB (RDEB) patients. The authors reported iron,
vitamin D, C, B6, PP, zinc, and selenium deficiencies in
36–70 % of the patients, while vitamin B1, B12, B2, A,
retinol binding protein and carnitine levels were within
the relevant reference interval. For the first time, on the
basis of these considerations, we evaluated, homocyst-
eine status by assessing tHcy levels and metabolically re-
lated vitamins in 20 EB children and adolescents and
compared them to those of a healthy population well-
matched for age and gender. Our results showed tHcy
levels above the cut-off value in more than 50 % of EB
patients. Particularly, even if tHcy levels did no differ be-
tween EBS subjects and controls, DEB subjects’ tHcy
levels were higher than in controls.
Analysing Hcy related vitamins our results concerning
B6 were in agreement with previous findings [14, 15]; in
fact, plasma B6 levels were under the lower limit of the
reference interval in most of our patients [12] and lower
in EB patients than in controls. As regards this vitamin
deficiency, B6 levels in EB patients with weight under
the 3rd percentile, differed from B6 levels of patients with
weight above the 10th percentile. A plausible explanation
of this deficiency was due to the EB patients’
undernourishment.
Shen J et al. [16] reported that plasma pyridoxal 5’-
phosphate (PLP), the biologically active form of vitamin
B6, was adversely associated with inflammatory markers,
such as CRP, fibrinogen, and blood cell count. In
addition, an inverse relationship between CRP and PLP
has also been found among participants in the Framing-
ham Heart Study and the National Health and Nutrition
Examination Survey (NHANES) [17]. Current evidence
Table 3 Biochemical parameters of patients and controls
Analyte (reference interval or cut-off) EB patients (n = 20) Controls (n = 20) p*
tHcya
(1 < 7 years; 2.7-7.6 μmol/L
7 < 12 years; 3.4 -8.4 μmol/L
12 < 15 years; M: 4.7-10.4 μmol/L; F: 4.1-10.4 μmol/L
15 < 19 years; M: 5.5-13.4 μmol/L; F: 4.9-11.9 μmol/L)
9.9;7.5-10.5
(55 %)
6.5;5.8-8.4
(15 %)
0.04
[0.02]
B12
a
(1 < 9 years; 208.8- 1190 pmol/L
9 < 14 years; 185.9-830.2 pmol/L
14 < 17 years; 180.1-655.3 pmol/L
17 < 19 years; 149.8-598.5 pmol/L)
583.4;402.2-822.3
(0 %)
468.8;360.2-652.9
(5 %)
0.30
[1.00]
HoloTC
(>40 pmol/L)
99.2;79.7-128
(10 %)
84.9;51.1-128
(10 %)
0.42
[0.60]
s-Fb
(0-15 years; 11.6-33.2 nmol/L
15-65 years; 5.8-28.6 nmol/L)
11.1;8.4-21.3
(50 %)
13.1;11.1-15.7
(20 %)
0.64
[0.10]
ery-Fb
(2-15 years; 409.9-1162 nmol/L)
843.3;591.0-1559.7
(10 %)
608.4;556.3-742.5
(10 %)
0.10
[0.60]
B6
b
(2-5 years; 10.0-21.6 μg/L
9-13 years; 9.6-24.4 μg/L)
6.9;4.2-12.3
(70 %)
11.3;9.2-14.3
(25 %)
0.03
[0.01]
hsCRP
(<0.5 mg/dL)
0.55;0.01-3.1
(50 %)
0.05;0.03-0.16
(0 %)
0.003
[0.00]
Data are reported as median;IQR. Percentage of altered values are reported in parentheses (%). *Mann-Whitney test [chi-square test]
a Bailey D. et al. [11]; b Ortega RM. et al. [12]. tHcy: total Homocysteine; B12: vitamin B12; HoloTC: Holotranscobalamin; s-F: serum Folate; ery-F: intraerythrocyte; B6:
vitamin B6; hsCRP: high sensitive C Reactive Protein
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suggests that the inverse association between plasma
PLP and inflammation may be the result of this coen-
zyme used by the PLP-dependent enzymes for the
kynurenine pathway of tryptophan degradation, for the
metabolism of the immunomodulatory sphingolipids,
ceramide and sphingosine 1-phosphate, and for serine
hydroxymethylase for immune cell proliferation [17, 18].
According to the previous findings [17, 18], in the
present study an inverse correlation was found between
B6 levels and hsCRP in EB patients. In fact, our EB pa-
tients showed hsCRP levels higher than controls and,
interestingly, higher in DEB than in EBS. No difference
was found between EBS and controls. This was probably
due to the extent of blistering and ulcerations, under-
lying a possible correlation between the severity disease
and the inflammatory degree. Therefore, we hypothe-
sized that B6 deficiency was not only a consequence of
undernourishment but was also related to the systemic
inflammation which characterized these patients.
Ery-F concentration is a reliable indicator of long-term
folate status and general dietary intake, and s-F of more
recent intake; a more comprehensive estimate of total
folate status is generally obtained by assessing both pa-
rameters, as reported in this and in our previous studies
[19–21]. In the present study, 50 % of the patients had
altered s-F values due to undernourishment; in fact, in
patients whose weight was under the 3rd percentile, s-F
levels were lower than in the other patients. However,
s-Fol levels did not differ between the two groups,
underlying only a mild deficiency in EB subjects. This
was also confirmed by assessing ery-F levels which
were within the relevant reference interval both in
most patients and in controls and similar to those
obtained by Ortega RM et al. [12].
Fig. 1 Biochemical parameters analysis in EB patients and controls. a Box-and-Whisker plot of tHcy levels between EB patients and controls
(p = 0.04); b Box-and-Whisker plot of vitamin B6 levels between EB patients and controls (p = 0.03); c Box-and-Whisker plot of hsCRP levels
between EB patients and controls (p = 0.003). Data are reported as median;Interquartile range (IQR); d Correlation between vitamin B6 and hsCRP
levels in EB patients (p = 0.009)
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The determination of cobalamin status, by measuring
also HoloTC concentrations, represents an approach for
diagnosing subtle cobalamin deficiency. HoloTC, the
transcobalamin (TC)-cobalamin complex representing
the biologically active form of the vitamin and consisting
of 10 %–30 % of total serum B12, is recognized by ubi-
quitous specific membrane receptors and could have
high diagnostic value as a marker of storage [8]. It has
been demonstrated that HoloTC is a more sensitive
marker of vitamin B12 status compared with total serum
cobalamin [8], and it could be the earliest and most
sensitive marker for vitamin B12 deficiency [8]. Accord-
ing to Ingen-Housz-Oro S. et al’s study [14], B12 levels
were within the relevant reference interval in most
patients and controls; this was probably due to the
enterohepatic recycling preventing an early onset of
cobalamin deficiency [22]. Although HoloTC levels did
not differ significantly between the two groups, were
altered in 10 % of patients and controls. Additionally,
undernourished EB subjects weight <3rd percentile)
showed decreased HoloTC concentrations but vitamin
B12 levels within the relevant reference interval when
compared to the other well-nourished patients. Hence
the importance of HoloTC determination, as an early
marker of B12 deficiency, in order to monitor cobalamin
status.
However, in the present study it was considered the
HoloTC cut-off value of an adult population (cut-off
value >40 pmol/L) [8] and this possible limitation could
suggest that further studies are necessary in order to
assess HoloTC levels in a larger paediatric population
and create an appropriate cut-off value.
Finally, considering Hcy metabolism, despite the
presence of B6 and s-F deficiency in some patients, the
multiple linear regression analysis showed that tHcy
levels did not depend on the metabolically related
vitamins. A possible explanation is that it could be
related to the limited number of studied patients; further
studies are required to extend these preliminary results
by expanding EB population.
A well-known fact is that even among EB patients
within the same EB type, clinical symptoms could vary
significantly as regards the severity of the disease. The
nutritional status of these patients does not always
correlate with their genetic diagnosis but is rather
related to the clinical symptoms and could also be influ-
enced by other socio-economic factors [23]. Therefore,
in the present study, we scored disease severity for each
patient using the BEBS [9] which might help to
characterize patients with unexpectedly mild or severe
disease, and contributing to genotype phenotype correl-
ation [9]. As previously reported by other authors [9],
BEBS score correlated positively with age, suggesting
that changes in BEBS score reflect clinical observations,
particularly disease progression with age. Additionally,
BEBS score confirmed the B6 deficiency due to under-
nourishment and severe inflammation and the useful-
ness of HoloTC as an early marker of B12 deficiency.
The findings of our study are in agreement with the
aforementioned consideration, particularly as regards BMI
and B6 levels; in fact, in our population, 1 DDEB patient,
despite the genetic diagnosis, showed good clinical symp-
toms (BEBS score = 2), BMI >95th percentile and normal
B6 levels. On the contrary, 3 EBS patients (BEBS score: 8;
17; 25) showed BMI <3rd percentile and B6 levels under
the lower limit of the reference interval [12].
Conclusions
EB patients are at risk of severe nutritional deficiencies;
to the best of our knowledge, this is the first study that
took into consideration the possible nutritional deficien-
cies (B vitamins group) of young EB patients by evaluat-
ing Hcy status.
Most of EB patients showed tHcy levels above the cut-
off value, probably due to the S-F and B6 levels defi-
ciency. In fact, S-F levels decreased in half of the
patients and even more so in the undernourished ones.
However, by comparing EB patients’s-F levels with con-
trols’, we noticed only a mild deficiency in EB patients.
The consistent B6 deficiency was due not only to the
undernourishment but also to the severe inflammation
which in turn was underlined by an increase in EB
patients’ hsCRP levels.
Finally, tHcy levels were not correlated significantly
with metabolically related vitamins deficiency (particu-
larly S-F levels and B6), because the limited number of
studied cases.
In addition, we also reported the importance of
HoloTC evaluation as an early marker of cobalamin
deficiency.
In conclusion, monitoring tHcy and metabolically
related vitamin levels enable us to describe the EB
patients’ nutritional status could represent an essential
aspect of their long term care. Monitoring B6 levels is
particularly important in order to avoid both a number
of complications associated with B6 deficiency and an
excess of B6 which sustains an inflammatory condition.
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